Mindshift Compounds News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mindshift compounds. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mindshift Compounds Today - Breaking & Trending Today

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public


Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Compass Pathways (NASDAQ:CMPS) and
MindMed (NASDAQ:MNMD) remain the only two companies in psychedelics to reach a major U.S. stock exchange. Both companies presented net losses associated with R&D expenses, as entities in the space race towards gaining ground in a sector that still hasn’t reached early maturity or profitability.
Both companies presented strong cash positions to advance their research pipelines.
Compass, Pressing On Psilocybin: Compass highlighted the issuing of two new patents and a post-quarter equity financing round of $144 million. ....

University Of The West Indies , Saint Andrew , Costa Rica , Rick Doblin , Douglask Gordon , Kaivalya Kollectiv , Daniel Carcillo , Braxia Scientific Corp , Wesana Health Goes Public , Intelgenx Technologies Corp , Excellence Inc , Multidisciplinary Association Of Psychedelic , Wesana Health Holdings Inc , Canadian Securities Exchange , Canadian Rapid Treatment Center , Braxia Health , Wake Network Inc , Drug Administration , Therapy Training Program , Atai Life Sciences , Office Of Neuroscience , Silo Wellness Inc , Research Deal With World Boxing Council , Jamaican Ministry Of Health , Havn Life Sciences Inc , World Boxing Council ,

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing


Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics psychiatry s brave new world. The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by leading pharmaceutical companies. A report from Data Bridge Market Research reported that the global psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key facto ....

United States , British Columbia , Nathan Bryson , Joe Flanders , Rupika Delgoda , Doug Drysdale , Dan Engle , Kelsey Ramsden , Cybin Inc , University Of West Indies , Fn Media Group , Development Laboratory For Psychedelic Fungi In Mona , Mindspace Psychology Services Inc , Natural Products Institute , Numinus Wellness Inc , Exchange Commission , Oxford University United Kingdom In Pharmacology , Numinus Inc , Cure Health , Market Research , Field Trip Natural Products Limited Research , Field Trip Health Ltd , Dan Engle As Primary Investigator For Research , Securities Exchange , Cure Health Inc , Data Bridge Market Research ,

MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC. (MMEDF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC. (MYCOF) - Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M


Mind Cure Closes $18M Raise
Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering.
The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit. 
The proceeds will be used to finance product research and development, advance the company’s technological capabilities, marketing expenditures and product awareness, as well as for working capital.
So far, Mind Cure has raised almost CA$31 million ($24.4 million) to date. The company’s operations are divided between five spheres, which include:
A line of non-psychedelic supplements using functional mushroom formulations that are already available to consumers. ....

Joshua Bartch , Miri Halperin Wernli , Felix Lustenberger , Trademark Office , Mydecine Innovations Group , Head Of Clinical Development , Pharmadrug Inc , Cure Health Inc , Mind Cure Closes , Cure Health , Mind Cure , Med Dives Into Psychedelics , Mindshift Compounds , Mindmed President , Clinical Development , Miri Halperin , Innovations Group , Orphan Drug Designation , Orphan Drug , மீறி ஹால்பெரின் வெற்ணிலி , முத்திரை அலுவலகம் , தலை ஆஃப் மருத்துவ வளர்ச்சி , குணப்படுத்த ஆரோக்கியம் இன்க் , மனம் குணப்படுத்த மூடுகிறது , குணப்படுத்த ஆரோக்கியம் , மனம் குணப்படுத்த ,